Jobs
-
According to reports, Johnson & Johnson described development of a ketamine nasal spray for the treatment of depression during a meeting with analysts on May 23, 2013. The product is not listed among the company’s… Read more . . .
-
Despite most delegates having partied past midnight at the previous night’s gala dinner, the 8:30 a.m. session on “Designing Devices for the Marketplace” Day 3 of RDD Europe 2013 was very well attended. . .… Read more . . .
-
On Day 2 of RDD Europe 2013, the focus was primarily on regulatory issues. . . . Read more Read more . . .
-
A new consortium described as a “series of conceptual research projects in the area of nasal physiology, function and drug delivery” that “aims to enhance understanding in the area of upper respiratory tract disorders and… Read more . . .
-
On the morning of May 22, one of the organizers of RDD Europe 2013, Peter Byron, opened the meeting by welcoming approximately 470 delegates back to Berlin.. . . Read more Read more . . .
-
A study presented at ATS 2013 found that over 40 percent of uninsured patients treated for COPD at a US clinic did not actually have COPD. Researchers from Northeast Ohio Medical University and Saint Elizabeth… Read more . . .
-
Prosonix has started a Phase 2 safety and dose-ranging study of PSX1002 inhaled glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA), in patients with moderate-to-severe COPD, the company has announced. The suspension formulation of PSX1002 engineered… Read more . . .
-
Grifols is paying $25 million upfront, plus up to $25 million in milestone payments to acquire a worldwide license for Aradigm’s Pulmaquin and Lipoquin inhaled ciprofloxacin formulations. Grifols will also pay tiered royalties on worldwide… Read more . . .
-
Malvern Instruments has announced that it will team up with Proveris Scientific Corporation on a nasal spray characterization system called Solo for Spraytec, which combines Proveris’s automated actuator and software for precise control of device… Read more . . .
-
Inhaled drug developer Vectura has announced better than expected preliminary results for the year ending March 31, 2013, with the company’s loss before tax 21% lower than in 2011/12. The company also announced that Paul… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK